222 related articles for article (PubMed ID: 17254529)
21. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
22. Imatinib in the treatment of dermatofibrosarcoma protuberans.
Labropoulos SV; Razis ED
Biologics; 2007 Dec; 1(4):347-53. PubMed ID: 19707305
[TBL] [Abstract][Full Text] [Related]
23. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
24. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
26. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP).
Stacchiotti S; Pantaleo MA; Negri T; Astolfi A; Tazzari M; Dagrada GP; Urbini M; Indio V; Maestro R; Gronchi A; Fiore M; Dei Tos AP; Conca E; Palassini E; Vincenzi B; Grosso F; Pilotti S; Castelli C; Casali PG
Clin Cancer Res; 2016 Feb; 22(4):837-46. PubMed ID: 26261104
[TBL] [Abstract][Full Text] [Related]
28. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment.
Sirvent N; Maire G; Pedeutour F
Genes Chromosomes Cancer; 2003 May; 37(1):1-19. PubMed ID: 12661001
[TBL] [Abstract][Full Text] [Related]
29. [Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].
Zhu JH; Li QW; Xiao WH; Sun JZ; Wang RL; Lu JY
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):470-2. PubMed ID: 21875491
[TBL] [Abstract][Full Text] [Related]
30. Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans: A Systematic Review.
Navarrete-Dechent C; Mori S; Barker CA; Dickson MA; Nehal KS
JAMA Dermatol; 2019 Mar; 155(3):361-369. PubMed ID: 30601909
[TBL] [Abstract][Full Text] [Related]
31. [Dermatofibrosarcoma protuberans].
Sanmartín O; Llombart B; López-Guerrero JA; Serra C; Requena C; Guillén C
Actas Dermosifiliogr; 2007 Mar; 98(2):77-87. PubMed ID: 17397592
[TBL] [Abstract][Full Text] [Related]
32. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Rutkowski P; Van Glabbeke M; Rankin CJ; Ruka W; Rubin BP; Debiec-Rychter M; Lazar A; Gelderblom H; Sciot R; Lopez-Terrada D; Hohenberger P; van Oosterom AT; Schuetze SM; ;
J Clin Oncol; 2010 Apr; 28(10):1772-9. PubMed ID: 20194851
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
34. Dermatofibrosarcoma Protuberans.
Allen A; Ahn C; Sangüeza OP
Dermatol Clin; 2019 Oct; 37(4):483-488. PubMed ID: 31466588
[TBL] [Abstract][Full Text] [Related]
35. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
37. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
[TBL] [Abstract][Full Text] [Related]
38. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
Stacchiotti S; Pedeutour F; Negri T; Conca E; Marrari A; Palassini E; Collini P; Keslair F; Morosi C; Gronchi A; Pilotti S; Casali PG
Int J Cancer; 2011 Oct; 129(7):1761-72. PubMed ID: 21128251
[TBL] [Abstract][Full Text] [Related]
39. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
[TBL] [Abstract][Full Text] [Related]
40. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
